Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce today a…
Browsing: Pharma
Parties agree to collaborate on research in genetics, regenerative and alternative medicine Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource…
Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at…
Global markets in sight for shariah-compliant IndoVac vaccine brand PT Bio Farma, the holding company for state-owned pharmaceutical companies in…
Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3…
Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations,…
Meet the team at Booth #409 Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with…
Legend Capital recently announced that it made its 100th IPO following the listing of its AI medical portfolio company Lunit…
Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled “Evolution…
As pharmaceutical reformation is underway, the importance of the innovative strength of biotech companies has become increasingly prominent, the entire…
Pursuing Progress in Revenue, Increased by 14.1% Ensuring Stability and Accommodating the Needs for Pandemic Control The board of directors…
AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, has been acquired by biotech investor Dr. Glenn Haifer and Ampersand…
Application Scenario Solutions Open Up Broad New Prospects in Assisted Reproduction Suzhou Basecare Medical Corporation Limited (Basecare Medicalor the Company,…
Avance Clinical, the leading Australian CRO for international biotechs, is sponsoring two awards – Biotech Company of the Year Private…
Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has…
— NVK002 completed patient recruitment for both concurrent Phase III clinical trials significantly ahead of schedule — First commercialized product,…
Avantor Foundation, Avantor’s philanthropic arm, committed financial resources to healthcare charitable organizations, HealthServe and SATA CommHealth, as part of the…
SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group, HKG: 3681), a Hong Kong-based biopharmaceutical company…
Positive Phase 2 data, published in Clinical Ophthalmology, highlights the potential of licaminlimab to become a novel treatment in DED…
Benefitted from Years of Huge Investment in R&D Sales of New Products Accounts for 43.5% of Revenue Sino Biopharmaceutical Limited…